Business Context and Reporting Period
This Form 8-K is a current report filed by Werewolf Therapeutics, Inc. (Nasdaq: HOWL) on May 13, 2025. The filing addresses a regulatory notice regarding the company's continued listing status on the Nasdaq Global Select Market.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only quantitative metric disclosed is the stock price performance:
- Stock Price Deficiency: The closing bid price of the Company's common stock was below $1.00 per share for the last 30 consecutive business days prior to May 13, 2025.
Material Changes
The material event reported is the receipt of a deficiency letter from the Nasdaq Listing Qualifications Department. This notice indicates a failure to satisfy the Minimum Bid Requirement (Nasdaq Listing Rule 5450(a)(1)), which mandates a minimum bid price of $1.00 per share to maintain listing on the Nasdaq Global Select Market.
Outlook, Risks, and Contingencies
Compliance Timeline: The Company has an initial period of 180 calendar days (expiring November 10, 2025) to regain compliance. To do so, the stock must close at or above $1.00 for 10 consecutive business days within this window.
Contingency Plans: If the Company fails to regain compliance in the initial period, it may be eligible for an additional 180-day period, provided it transfers its listing to the Nasdaq Capital Market and meets that market's listing standards (excluding the bid price requirement).
Risks:
- There is no assurance the Company will regain compliance with the Minimum Bid Requirement.
- If the Company fails to cure the deficiency during the second compliance period, or fails to meet other listing standards, the stock may be subject to delisting.
- Any appeal of a delisting determination to a Hearings Panel is not guaranteed to be successful.
Investor Verification Checklist
- Verify the current closing bid price of HOWL stock to assess proximity to the $1.00 threshold.
- Monitor the Company's stock performance over the next 10 consecutive business days to determine if the initial compliance window is being utilized.
- Review future filings for any announcements regarding a potential transfer to the Nasdaq Capital Market.
- Check for any reverse stock split proposals, which are a common method for companies to address low bid price deficiencies (though not explicitly mentioned in this text).